search
Back to results

Indication of Permanent Cardiac Parcing After Tanscatheter Aortic Valve Implantation (TAVISTIM)

Primary Purpose

Aortic Valve Stenosis

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Pacemaker SORIN Group KORA DR
transcatheter aortic valve implantation (TAVI)
Sponsored by
University Hospital, Montpellier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Aortic Valve Stenosis focused on measuring TAVI, complete AV-block, HV-interval, permanent pacemaker, valve implantation, severe, conduction, disorders

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patient undergoing TAVI through femoral approach
  • age > 50 years
  • informed and written consent
  • patient with social security system

Exclusion criteria:

  • patient with previous pacemaker or ICD
  • patient under guardianship or curatorship
  • patient protected by law

Sites / Locations

  • University Hospital Arnaud de Villeneuve

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Pacemaker

No Pacemaker

Arm Description

Patient who have been implanted with a pacemaker after TAVI

Patient who have not been implanted with a pacemaker after TAVI

Outcomes

Primary Outcome Measures

to confirm appropriate pacing indication in patients with conduction disorders after TAVI
Pacemaker implantation will be confirmed if there is more than 1% of ventricular pacing or at least one DDD mode switch in the memories. In non-implanted patients, the non-indication for pacing was confirmed in the absence of clinical event and 24-hour Holter ECG recording abnormality.

Secondary Outcome Measures

Measures electrocardiographic characteristics before and after implantation
QRS width (milliseconds), space PR (milliseconds), presence of conduction disorders (atrioventricular block, block right or left branch), axis (degrees), sinus rhythm (yes / no)
Measures echographic characteristics
LVEF (in%), aortic valve area (cm2 / m2), aortic regurgitation (grade I / IV)
Type of bioprosthesis
CoreValve, Edwards
Positioning bioprosthesis
high or low relative to the ring plane
Diameter of the implanted bioprosthesis and ratio with the surface of the patient's aortic valve
Taking bradycardia preoperative treatment
yes/no
Electrophysiological data
HV interval measurement before and after the intervention (ms)
Diameter ratio of pre-dilation balloon used during the procedure compared to the patient's valve area
Clinical characteristics
ischemic heart disease history (specify bypass or angioplasty), cardiovascular risk factors (hypertension, diabetes, obesity, smoking ...), patient age
biological characteristics
creatinine before surgery, troponin after surgery

Full Information

First Posted
August 11, 2014
Last Updated
November 30, 2016
Sponsor
University Hospital, Montpellier
search

1. Study Identification

Unique Protocol Identification Number
NCT02337140
Brief Title
Indication of Permanent Cardiac Parcing After Tanscatheter Aortic Valve Implantation
Acronym
TAVISTIM
Official Title
Indication of Permanent Cardiac Parcing After Tanscatheter Aortic Valve Implantation : Contribution of Electrophysioly Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
August 2014 (undefined)
Primary Completion Date
April 2016 (Actual)
Study Completion Date
August 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Since 2002, transcatheter aortic valve implantation (TAVI) has resulted in a dramatic change in the prognosis of patients with aortic valve stenosis illegible to surgery. However, this intervention may induce heavy conduction disorder due to the proximity of the aortic annulus and the conduction pathways. So far, there is no clear recommandation for clinical management of conduction disorder after TAVI. Standard criterion cannot be applied due to the multiple comorbidity factors observed in these patients. As described in conventional aortic valve surgery, a degree of inflammation and ischemia of the conduction pathways may be involved in the first days. This is the reason underlying the systematic implantation of epicardial electrodes. Such temporary back-up pacing is not possible in TAVI patients. The primary end-point of this study is to confirm that standard criterion for pacing are reliable in post-TAVI conduction disorders and to analyze the contribution of a systematic electrophysiological study (EPS). In TAVI patients, indications for pacing were persistent high-degree atrioventricular block (AVB) or bundle branch block appearance associated to HV interval longer than 70ms, 24 hours after the procedure. After a two-month follow-up, clinical and ECG evaluation and 24-hour holter monitoring will be realized in patients without pacemaker and compared to data obtained from the devices in pacemaker-implanted patients (% of ventricular pacing > 1% ; presence of more than 1 AVB episod).
Detailed Description
Inclusions will take place from August 2014 to February 2015. We plan to include 165 consecutive patients with TAVI through a femoral approach. At the inclusion, clinical baseline and electrocardiographic data will be collected. During the procedure, baseline ECG data as well as conduction disorders will be recorded. An EP study will be performed (measure of AH and HV intervals) before and after TAVI. Aortic surface area, transvalvular mean gradient, presence of periprothetic leak and LV ejection fraction will be determined by echocardiography within the first 24 hours. After the procedure, a 24-hour ECG monitoring will be done in ICU. A pacemaker will be implanted in case of persistent severe conduction disorders at 24 hours post-TAVI . All patients will be implanted with SORIN Group KORA DR devices to benefit from the AAI-SafeR mode and the AVB episodes automated analysis. All implanted pacemakers will be settled with identical parameters to allow appropriate patient data analysis (AAI-SafeR for sinus rhythm patients and VVIR in chronic atrial fibrillation patients). In patients with 24-hour persistence of bundle branch block onset after TAVI, a repeated EPS with HV recording will be performed. If HV interval is > 70ms, a pacemaker will be implanted and the patient will be added to the pacemaker-implanted patients. In the absence of persistent conduction disorder 24h after the procedure, no specific supervision will be done. All patients will have a 2-month follow up. At this time, clinical, ECG and echocardiographic data will be collected. Additional 24-hour Holter ECG monitoring will be performed in non-implanted patients and additional device control will be performed in implanted patients. Pacemaker implantation will be confirmed if there is more than 1% of ventricular pacing or at least one DDD mode switch. In non-implanted patients, the non-indication for pacing was confirmed in the absence of clinical event and 24-hour Holter ECG recording abnormality. The secondary endpoint of the study is to define a posteriori risk factors for pacemaker implantation after TAVI included in the liste hereafter: Clinical data: age, drug-induced bradycardia, hypertension, ischemic cardiomyopathy, creatinin clearance, troponin value. Electrocardiographic data: QRS duration, PR interval, preexisting bundle branch block or AV block, QRS axis, sinus rhythm Echocardiographic data : aortic surface area, LV ejection fraction, aortic annulus/prothesis ratio, aortic annulus/balloon diameter ratio Electrophysiological data : HV interval before and after TAVI

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Valve Stenosis
Keywords
TAVI, complete AV-block, HV-interval, permanent pacemaker, valve implantation, severe, conduction, disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
165 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pacemaker
Arm Type
Experimental
Arm Description
Patient who have been implanted with a pacemaker after TAVI
Arm Title
No Pacemaker
Arm Type
Active Comparator
Arm Description
Patient who have not been implanted with a pacemaker after TAVI
Intervention Type
Device
Intervention Name(s)
Pacemaker SORIN Group KORA DR
Intervention Type
Procedure
Intervention Name(s)
transcatheter aortic valve implantation (TAVI)
Primary Outcome Measure Information:
Title
to confirm appropriate pacing indication in patients with conduction disorders after TAVI
Description
Pacemaker implantation will be confirmed if there is more than 1% of ventricular pacing or at least one DDD mode switch in the memories. In non-implanted patients, the non-indication for pacing was confirmed in the absence of clinical event and 24-hour Holter ECG recording abnormality.
Time Frame
2 months
Secondary Outcome Measure Information:
Title
Measures electrocardiographic characteristics before and after implantation
Description
QRS width (milliseconds), space PR (milliseconds), presence of conduction disorders (atrioventricular block, block right or left branch), axis (degrees), sinus rhythm (yes / no)
Time Frame
2 months
Title
Measures echographic characteristics
Description
LVEF (in%), aortic valve area (cm2 / m2), aortic regurgitation (grade I / IV)
Time Frame
2 months
Title
Type of bioprosthesis
Description
CoreValve, Edwards
Time Frame
2 months
Title
Positioning bioprosthesis
Description
high or low relative to the ring plane
Time Frame
2 months
Title
Diameter of the implanted bioprosthesis and ratio with the surface of the patient's aortic valve
Time Frame
2 months
Title
Taking bradycardia preoperative treatment
Description
yes/no
Time Frame
2 months
Title
Electrophysiological data
Description
HV interval measurement before and after the intervention (ms)
Time Frame
2 months
Title
Diameter ratio of pre-dilation balloon used during the procedure compared to the patient's valve area
Time Frame
2 months
Title
Clinical characteristics
Description
ischemic heart disease history (specify bypass or angioplasty), cardiovascular risk factors (hypertension, diabetes, obesity, smoking ...), patient age
Time Frame
2 months
Title
biological characteristics
Description
creatinine before surgery, troponin after surgery
Time Frame
2 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patient undergoing TAVI through femoral approach age > 50 years informed and written consent patient with social security system Exclusion criteria: patient with previous pacemaker or ICD patient under guardianship or curatorship patient protected by law
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
THOMANN SARAH, MD
Organizational Affiliation
University Hospital, Montpellier France
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Arnaud de Villeneuve
City
Montpellier
ZIP/Postal Code
34295
Country
France

12. IPD Sharing Statement

Learn more about this trial

Indication of Permanent Cardiac Parcing After Tanscatheter Aortic Valve Implantation

We'll reach out to this number within 24 hrs